Importance of Testing

 

 

PD-L1 is commonly expressed in UC

 

Prevalence of PD-L1 expression in urothelial carcinoma
Prevalence of PD-L1 expression in urothelial carcinoma

Find out how many patients in your practice may express PD-L1 using the Prevalence Calculator.

Find out how many patients in your practice may express PD-L1 using the Prevalence Calculator.

 

PD-L1 expression may indicate dependence on the PD-1/PD-L1 pathway3,4

 

PD-L1 staining patterns in UC5

 

Low TC and IC expression*High TC and/or IC expression*

 

Reproduced with permission from Massard et al.5

Reproduced with permission from Massard et al.5

Range of PD-L1 expression in urothelial carcinoma
Range of PD-L1 expression in urothelial carcinoma

Expression of PD-L1 on TCs and ICs can vary within tissue samples.5

 

Reproduced with permission from Massard et al.5

Response icon
Response icon

Although patients with low PD-L1 expression respond to anti–PD-1/PD-L1 therapy, patients with high PD-L1 had5-9:

 

• Higher response rates

• Longer progression-free survival

• Longer overall survival

FDA-approved anti–PD-1/PD-L1 therapies are available10:

FDA-approved anti–PD-1/PD-L1 therapies are available10:

 

Check box icon
Check box icon

Knowing a patient’s PD-L1 status can help set expectations for patients and caregivers about response to therapy.5-9 

 

FDA, Food and Drug Administration; IC, immune cell; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; TC, tumor cell; UC, urothelial carcinoma.

 

*Stained using the Ventana SP263 Assay. PD-L1 staining from left to right: <25% TC and <25% IC (TC-negative/IC-negative); <25% TC and ≥25% IC (TC-negative/IC-positive); ≥25% TC and <25% IC (TC-positive/IC-negative); ≥25% TC and ≥25% IC (TC-positive/IC-positive).

 

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

 

References: 1. Inman BA et al. Cancer. 2007;109(8):1499-1505. 2. Wu CT et al. Sci Rep. 2016;6:19740. doi:10.1038/srep19740. 3. Beatty GL, Gladney WL. Clin Cancer Res. 2015;21(4):687-692. 4. McDermott DF, Atkins MB. Cancer Med. 2013;2(5):662-673. 5. Massard C et al. J Clin Oncol. 2016;34(26):3119-3125. 6. Powles T et al. Nature. 2014;515(7528):558-562. 7. Rosenberg JE et al. Lancet. 2016;387(10031):1909-1920. 8. Plimack ER et al. Lancet Oncol. 2017;18(2):212-220. 9. Sharma P et al. Lancet Oncol. 2016;17(11):1590-1598. 10. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Bladder Cancer V5.2018. © National Comprehensive Cancer Network, Inc. 2018. All rights reserved. Accessed September 27, 2018. To view the most recent and complete version of the guidelines, go online to NCCN.org.